Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Somatostatinoma 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Trastuzumab 2tipifarnib 1temsirolimus 1sapanisertib 1romidepsin 1pazopanib 1cixutumumab 1antineoplaston AS 2-1 1antineoplaston A10 1aflibercept 1Streptozocin 1Specimen Handling 1Sorafenib 1Sirolimus 1Salts 1Oxaliplatin 1Octreotide 1Nivolumab 1Magnetic Resonance Spectroscopy 1Leucovorin 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gefitinib 1Floxuridine 1Everolimus 1Disulfides 1Cytidine Triphosphate 1Complementary Therapies 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Somatostatinoma × Cytidine Triphosphate × Clear all
NCT02101918 2020-03-23

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 10 charts
Endocrine

Somatostatinoma, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡